Notably, targeting the CES1/PPARα/stearoyl-CoA desaturase 1 pathway has been reported to enhance the efficacy of cisplatin in hepatocellular carcinoma models, with coadministration reducing tumor growth in xenografted mice [33]. The gene discussed is CES1; the disease is neoplasm.